TVGN
Tevogen Bio Holdings·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Consensus Rating "Strong Buy"
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TVGN
Tevogen Bio Holdings Inc.
Clinical stage specialty immunotherapy biotechnology pioneer
Biological Technology
04/21/2021
01/04/2022
NASDAQ Stock Exchange
18
12-31
Common stock
15 Independence Boulevard, Suite #410, Warren, New Jersey 07059
--
Tevogen Bio Holdings Inc., incorporated in the Cayman Islands on April 21, 2021, was later merged and reorganized into a Delaware company. Tevogen Bio is a clinical stage professional immunotherapy company that utilizes one of nature's most powerful immune weapons — CD8 + cytotoxic T lymphocytes to develop off-the-shelf, ungenetically modified precision T cell therapies for the treatment of infectious, cancer and neurological diseases, aiming to address the significant unmet needs of a large patient population.
Company Financials
EPS
TVGN has released its 2025 Q3 earnings. EPS was reported at -0.03, versus the expected -0.06, beating expectations. The chart below visualizes how TVGN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
